TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Abera Bioscience AB
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Turnover |
0
|
238
|
0 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-96
|
-1,507
|
-1,742 |
| EBITDA |
-92
|
-1,514
|
-1,743 |
| Total assets |
1,184
|
843
|
1,759 |
| Current assets |
927
|
670
|
1,589 |
| Current liabilities |
431
|
333
|
251 |
| Equity capital |
754
|
510
|
1,508 |
| - share capital |
107
|
104
|
93 |
| Employees (average) |
5
|
6
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Solvency |
63.7%
|
60.5%
|
85.7% |
| Turnover per employee |
0
|
40
|
0 |
| Profit as a percentage of turnover | -633.2% | ||
| Return on assets (ROA) |
-8.1%
|
-178.8%
|
-99.0% |
| Current ratio |
215.1%
|
201.2%
|
633.1% |
| Return on equity (ROE) |
-12.7%
|
-295.5%
|
-115.5% |
| Change turnover | |||
| Change turnover % | -100% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % |
0%
|
20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.